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We show that the ubiquitin-associated domain (UBA) of human p62/sequestosome-1 (SQSTM1) can
delay degradation of proteasome substrates in yeast. Taking advantage of naturally occurring
mutant UBA domains that are linked to Paget’s disease of bone (PDB), we found that three of the
four mutant UBA domains tested in this study were able to inhibit proteasomal degradation, albeit
not to the same extent as the wild-type domain. Interestingly, the stability measured as the fraction
of folded protein, and not the ubiquitin binding properties, of the PDB-associated UBA domains cor-
related with their protective effects. These data suggest that the protective effect of UBA domains
depends on their structural integrity rather than ubiquitin binding capabilities.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction The complex nature of the UPS and the versatile behavior ofA unique and important feature of the ubiquitin/proteasome
system (UPS) is its ability to destroy proteins in a spatial and tem-
poral regulated manner by processive degradation [1]. Proteasomal
degradation is primarily regulated by means of conjugation of
canonical Lys48-linked polyubiquitin chains to substrates [2]. The
major determinants of protein turnover are degradation signals,
which are the motifs or domains that are recognized by ubiquitin
ligases [3]. Although ubiquitylation is intimately linked to prote-
asomal degradation, it has become apparent that various ubiquitin
modiﬁcations also play non-proteolytic roles in a number of pro-
cesses such as transcription and DNA repair [4].chemical Societies. Published by E
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a).ubiquitin modiﬁcations suggest that additional factors may be in-
volved in the regulation of ubiquitin-dependent proteolysis. Inter-
estingly, the C-terminal ubiquitin-associated (UBA)-2 domain of
the DNA repair and ubiquitin shuttling factor Rad23 [5] functions
as an intrinsic stabilization signal that prevents degradation of this
proteasome-interacting protein [6]. More recently, it was shown
that the transcription factor Met4, whose activity is regulated by
the conjugation of a Lys48-linked chain [7], was protected from
proteasomal degradation by a structurally unrelated ubiquitin
interacting motif (UIM) [8]. Biochemical analysis suggested that
the protective effect of the UIM was mediated through binding of
the UIM domain onto the Lys48-linked polyubiquitin chain on
Met4 whereby it prevented the formation of chains that were suf-
ﬁciently long to target for degradation [8]. Since Rad23’s UBA2 and
Met4’s UIM domains are structurally unrelated but share the abil-
ity to bind Lys48-linked polyubiquitin chains, a plausible explana-
tion seems that both domains act through a shared mechanism
that relies on ubiquitin binding.
Paget’s disease of bone (PDB) is a common chronic disorder that
is characterized by a focal increase in bone turnover causing
fractures and bone deformations [9]. The etiology of the diseaselsevier B.V. All rights reserved.
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[10]. Mutations in the ubiquitin binding protein p62, also known
as sequestosome-1 (SQSTM1), have been genetically linked to spo-
radic and familial cases of PDB [11]. Interestingly, the more than 20
PDB mutations in p62 that have been described are clustered with-
in, or adjacent to, the C-terminal UBA domain [11–16]. In the pres-
ent study, we have taken advantage of four of these naturally
occurring mutant UBA domains and used them to study the role
of ubiquitin binding and structural integrity in UBA-mediated pro-
tection from proteasomal degradation.2. Materials and methods
2.1. Yeast strains and media
The experiments were performed with haploid derivates of
strain DF5 (lys2-801, leu2-3, -112, ura3-52, his3-D200, trp1-1,
Mat-a). Yeast transformed with pYES2 plasmids encoding the indi-
cated reporter substrates were grown successively overnight in
synthetic minimal medium with a mix of glucose, rafﬁnose, and
galactose as sole carbon source until midlog phase. Yeast used in
experiments with proteasome inhibitor was grown for 2 h in the
presence of 50 lM proteasome inhibitor Z-Leu-Leu-Leu-CHO
(MG132; ENZO). To allow uptake of the inhibitor, yeast was grown
in synthetic medium with 0.1% proline as sole nitrogen source and
0.003% SDS [17]. Expression from the GAL1 promoter was regu-
lated by using the following mixtures of galactose, rafﬁnose and
glucose as carbon sources: 2.0% galactose (high expression), 1.4%
galactose and 1.0% rafﬁnose and 0.4% glucose (moderate expres-
sion) or 0.8% galactose and 1.0% rafﬁnose and 0.8% glucose (low
expression).
2.2. Construction of plasmids
Yeast expression plasmids were generated by PCR amplifying
the open reading frames, introducing ﬂanking restriction sites,
and cloning them into the yeast expression vector pYES2 Ub-M-
GFP and Ub-R-GFP [18]. The UBA domains that were inserted in
the fusions compromised the amino acids 388–440 of human p62.
2.3. Protein analysis
Yeast was grown in galactose until midlog phase. Total protein
extracts were obtained by lysis of the yeast and precipitation of
proteins in trichloroacetic acid. Protein turnover was determined
by administration of glucose and cycloheximide (Sigma) to ﬁnal
concentrations of 2% and 1 mg/ml, respectively, to the yeast cul-
tures in midlog phase. Aliquots were taken at the indicated time
points and total protein extracts were prepared. Samples were
heated at 95 C and subjected to SDS–PAGE for Western blot
analysis.
2.4. Western blot analysis
Total lysates were separated by SDS–PAGE and transferred to
nitrocellulose membranes (PROTRAN; Schleicher & Schuell). The
membranes were blocked in phosphate-buffered saline supple-
mented with 5% skim milk and 0.1% Tween-20 and incubated with
mixed monoclonal antibody (Roche) or polyclonal antibody
(Molecular Probes) speciﬁc to GFP. For loading controls, blots were
probed with a monoclonal antibody against b-actin (Abcam). After
subsequent washing steps and incubation with peroxidase-conju-
gated goat anti-mouse serum (GE Healthcare) or goat anti-rabbit
serum (Jackson ImmunoResearch Laboratories, Inc.), the blots were
developed with enhanced chemiluminescence (GE Healthcare).2.5. Flow cytometric analysis
Yeast was grown in galactose until midlog phase and subjected
to ﬂow cytometric analysis on a ﬂuorescence activated cell sorter
(FACScalibur; Beckton & Dickinson). The data were analyzed with
Cellquest software.2.6. Circular dichroism
The expression and puriﬁcation of the domains have been de-
scribed previously [19,20]. Far UV-circular dichroism (CD) spectra
were collected on an Applied PhotoPhysics Pi-star-180 spectropho-
tometer with a Peltier heating device for melting studies. In equi-
librium studies the temperature was regulated using a Neslab RTE-
300 circulating programmable water bath and spectra were col-
lected using a 10 mm path length quartz cuvette over a wavelength
range from 215–340 nm on 5 lM solutions of protein in 50 mM
phosphate buffer at pH 7.0. The melting curves were normalized
by converting to the fraction of protein folded as a function of tem-
perature. Lines of best ﬁt to the data represent the least squares ﬁt
to a simple two-state unfolding model from which the mid-point
of the transition could be determined (Tm).3. Results
3.1. Wild-type and mutant UBA domains of p62 can function as cis-
acting stabilization signals
We ﬁrst determined whether the wild-type UBA domain of hu-
man p62 can inhibit proteasomal degradation. For this purpose, we
expressed chimeric proteins that consisted of a proteasome repor-
ter substrate harboring an N-end rule degradation signal and the
wild-type or mutant UBA domains at their C terminus (Fig. 1A).
As an N-end rule substrate, we used ubiquitin-arginine-green ﬂuo-
rescent protein (Ub-R-GFP) which, upon processing by endogenous
deubiquitylation enzymes, exposes a destabilizing N-terminal argi-
nine residue that targets the fusion for ubiquitin-dependent degra-
dation [21]. As a control, we used ubiquitin-methionine-green
ﬂuorescent protein (Ub-M-GFP) in which the critical arginine resi-
due had been replaced by a methionine residue and that is hence
not targeted for proteasomal degradation. Yeast expressing Ub-R-
GFP contained much lower steady state GFP levels than Ub-M-
GFP as evidenced by Western blotting (Fig. 1B) and ﬂow cytometry
(Fig. 1C), as shown previously [18]. Notably, the Ub-R-GFP levels,
but not Ub-M-GFP levels, increased upon treatment with the pro-
teasome inhibitor MG132 consistent with efﬁcient proteasomal
degradation of Ub-R-GFP (Fig. 1B).
Introduction of the wild-type UBA domain of p62 in Ub-R-GFP
caused a signiﬁcant increase in the steady state levels of the sub-
strate (Fig. 1B and C), suggesting that this domain can delay prote-
asomal degradation. All four PDB-associated mutant domains, that
were used in this study, have a reduced ability to bind ubiquitin in
pull-down assays when present in full length p62 [22]. Isolated re-
combinant UBAM404T and UBAG425R domains are also severely im-
paired in ubiquitin binding whereas recombinant UBAP392L and
UBAG411S domains are still able to bind ubiquitin comparable to
the UBAWT [14]. We found that out of the four mutant domains
only the UBAM404T lacked a protective effect (Fig. 1B and C). Intro-
duction of the other three PDB-associated UBA domains, including
the UBAG425R, which exhibits severely impaired ubiquitin binding
in vitro [19], resulted in a signiﬁcant increase in the steady state
levels of the proteasome substrate although they did not reach
the same levels as observed with the wild-type domain. Notably,
the UBAG425R domain had a comparable protective effect to the
ubiquitin binding competent UBAP392L. These data suggest that
Fig. 1. Wild-type and mutant UBA domains of p62 can function as cis-acting stabilization signals. (A) Schematic drawing of the Ub-R-GFP N-end-rule reporter substrate fusion
protein and the UBA domain. The location of the UBA domain in p62 is indicated. (B) Steady state levels of Ub-M-GFP, Ub-R-GFP, or the Ub-R-GFP-UBA fusions in yeast in the
absence and presence of the proteasome inhibitor MG132. b-Actin is shown as a loading control. (C) Flow cytometric analysis of the GFP ﬂuorescence intensities of yeast
expressing Ub-R-GFP and the Ub-R-GFP-UBA fusions. For each construct the intensities of three samples, each consisting of a mixture of three colonies, was determined. The
values were standardized to the ﬂuorescence intensity of the Ub-R-GFP expressing strains. Mean and standard deviation are indicated (n = 6). Values that were signiﬁcantly
different from Ub-R-GFP are marked. *P < 0.05, **P < 0.01 (Student’s t test).
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proteasomal degradation mediated by UBA domains.
3.2. The UBA-mediated increase in Ub-R-GFP steady state levels is due
to prolonged half-lives
We next analyzed the effect of introducing the wild-type or
PDB-associated UBA domains on the half-lives of the substrate.
While the Ub-R-GFP was degraded within 10 min, the Ub-R-GFP-
UBAWT fusion was still present after 40 min (Fig. 2). Also the fu-
sions carrying the UBAG425R, UBAP392L or UBAG411S domains had in-
creased half-lives as compared with the Ub-R-GFP lacking a UBAFig. 2. The UBA-mediated increase in Ub-R-GFP steady state levels is due to
prolonged half-lives. Western blot analysis with GFP-speciﬁc antibody of turnover
of Ub-R-GFP and the Ub-R-GFP fusions in yeast at 0, 10, 20, and 40 min after
switching of protein synthesis by administration of glucose and cycloheximide.domain. The UBAG425R domain which is severely impaired in ubiq-
uitin binding and the ubiquitin binding competent UBAP392L had
the strongest stabilizing effects of the four mutant domains. The
UBAG411S domain gave a slightly weaker stabilization whereas
the UBAM404T domain was the only domain that was unable to de-
lay degradation of Ub-R-GFP.
3.3. The UBAM404T domain accelerates degradation
We next expressed the fusions in a yeast strain that due to a ge-
netic deletion lacked the Ubr1 ubiquitin ligase responsible for rec-
ognition and ubiquitylation of N-end rule substrates [23]. Ub-R-
GFP and all fusions with UBA domains except the Ub-R-GFP-
UBAM404T fusion were stable in the ubr1D strain (Fig. 3A). Although
the UBAM404T fusion was somewhat stabilized in the ubr1D, sub-
stantial residual degradation remained in the absence of the
Ubr1 ubiquitin ligase. Since the relative high expression levels ob-
tained from the GAL1 promoter could mask more subtle destabiliz-
ing effects of other mutant UBA domains, we reduced the
expression levels of the reporters by growing the yeast in the pres-
ence of a mixture galactose, rafﬁnose and glucose (Fig. 3B). Analy-
sis of the turnover of the fusions at this strongly reduced
expression level conﬁrmed that only the fusion containing
UBAM404T was still degraded in the absence of the Ubr1 ligase
(Fig. 3C). These data suggested that the Ub-R-GFP-UBAM404T is tar-
geted for degradation by the mutant UBA domain. Indeed, we ob-
served that insertion of the UBAM404T domain in the stable Ub-
M-GFP resulted in proteasomal degradation of this fusion
(Fig. 3D). These data show that the UBAM404T domain not only fails
to protect the substrate from degradation but accelerates its prote-
asomal degradation by a mechanism that is independent of the N-
end rule degradation signal.
Fig. 3. The UBAM404T domain accelerates degradation. (A) Turnover of the fusion proteins after promoter shutoff in the ubr1D yeast strain. Samples were collected at the
indicated time points after switching of protein synthesis by administration of cycloheximide and analyzed in anti-GFP Western blot analysis. (B) Steady state levels GAL1-
driven expression of Ub-R-GFP-UBAWT in ubr1D yeast grown in the presence of 2.0%, 1.4% or 0.8% galactose. b-Actin is shown as a loading control. (C) Turnover experiment as
in described in A but ubr1D yeast was grown in the presence of 0.8% galactose to reduce the expression level of the fusion proteins. (D) Steady state levels of Ub-M-GFP,
Ub-M-GFP-UBAWT, and Ub-M-GFP-UBAM404T in yeast in the absence and presence of proteasome inhibitor determined in a Western blot probed with a GFP-speciﬁc antibody.
b-Actin is shown as a loading control.
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CD spectroscopy
We investigated the structural integrity and relative stability of
the UBA domains using CD spectroscopy. The equilibrium CD spec-
tra were recorded at 298 K using the minimal UBA construct (387–
436), except in the case of the UBAP392L mutant which had addi-
tional N-terminal and C-terminal sequences (341–440). The
UBAM404V PDB mutant was also included in these biophysical anal-
yses, as our turnover experiments indicated M404 to be a critical
residue in the UBA domain. The CD spectra are typical of helix-rich
proteins with strong minima at 208 and 222 nm (Fig. 4A). The
spectra of the mutants generally overlay quite closely with that
of the wild-type UBA showing conservation of helical structure.
The spectrum of the 341–440 UBAP392L construct gives a greater
negative ellipticity at around 207 nm, reﬂecting the contribution
from the extended and ﬂexible N-terminal sequence [19]. We mea-
sured the thermal stability of the UBAs from CD melting proﬁles at
protein concentrations of 5 lM (representing the UBA monomer
[24]). The introduction of point mutations into the UBA domain
produces a signiﬁcant variation in stability with a 30 K range in
Tm values (Fig. 4B). A more useful measure of stability in this con-
text is to describe the fraction of folded protein (Uf) at a common
temperature. Since the protective effects of the domains were
studied at 303 K (30 C), a physiological temperature in budding
yeast, we estimated Uf also at this temperature (Fig. 4C). While
the UBAG425R and UBAP392L domains were essentially fully folded
at this temperature, a signiﬁcant proportion of the UBAG411S do-
main was unfolded and the UBAM404T and UBAM404V domains werehighly destabilized. We conclude that the protective effect of the
mutant UBA domains correlates with their thermal stability and
folding state at 30 C.
4. Discussion
Given the fact that the UIM domain of Met4 displays a protec-
tive effect by preventing the formation of polyubiquitin chains that
are sufﬁciently long to facilitate proteasomal degradation [8], it
seemed plausible that ubiquitin binding would also play a crucial
role in the molecular mechanism for UBA domain-mediated pro-
tection [6]. This hypothesis was in particular attractive since the
UBA and UIM domains are structurally unrelated but share the
ability to bind ubiquitin chains [25]. The observation that the
UBA domain of p62 can inhibit proteasomal degradation of repor-
ter substrates has opened the possibility to exploit a number of
naturally occurring UBA mutants that exert a range of effects on
ubiquitin binding [14,22]. Although this approach revealed that
ubiquitin binding activity is not directly related to UBA-mediated
inhibition of proteasomal degradation, the data do not exclude a
contributing role for ubiquitin binding since all PDB-associated do-
mains were less efﬁcient inhibitors than the wild-type UBA do-
main. Regardless whether ubiquitin binding or another feature
collectively absent in PDB-associated domains contributes to the
protective effect, our data unequivocally show that UBA domains
can inhibit proteasomal degradation even when their ubiquitin
binding activity is severely impaired. This strongly suggests that
the molecular mechanism is fundamentally different from that
proposed for Met4’s UIM domain.
Fig. 4. Thermal stability of PDB-associated UBA domains determined by CD
spectroscopy. (A) Equilibrium CD spectra recorded at 298 K for the wild-type UBA
and various PDB mutants. (B) Normalised CD melting curves for the UBA domains
showing the fraction folded as a function of temperature. The transition mid-point
(fraction folded = 0.5) enabled Tm values to be determined. The line of best ﬁt
represents the analysis of the transition in terms of a two-state unfolding model. (C)
Table showing the estimated Tm values for each UBA domain (error <0.5 K)
alongside the fraction of protein folded at 303 K.
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the UBA domain is accomplished. Our data show that mutant do-
mains with the greatest protective effects were the most thermally
stable indicating that structural integrity may play an important
role. In order for proteins to be degraded by the proteasome, the
polypeptide has to be unfolded and translocated into the proteo-
lytic chamber of the 20S core particle of the proteasome [26]. This
procedure is complex and requires accurate handling of the sub-
strate. Inhibition of a number of events crucial for protein degrada-
tion can account for the delayed degradation of UBA domain-
containing substrates including (1) substrate recruitment [27],
(2) the initiating step of unfolding [28], (3) substrate unfolding
[29], (4) the opening of the proteasome gate [30] and (5) substrate
translocation [26]. Therefore, further studies are required to empir-ically probe into the mode of action of UBA domain-mediated
stabilization.
Although we cannot formally exclude that this UBA domain
prevents proteasomal degradation of p62, this seems to be an un-
likely scenario given the biological functions of this protein. A
large body of evidence suggests that p62 primarily functions as
a scaffolding protein for ubiquitylated proteins in processes that
do not implicate proteasomal degradation, such as NF-jB signal-
ing [31] and macro-autophagy [32]. In line with this notion, we
did not observe an effect of the PDB-associated UBA domain
mutations on p62 turnover in human cells (CB, NPD; unpublished
observations), consistent with earlier studies [33]. Thus, our data
suggest that p62’s UBA domain is unlikely to play a role in pro-
tecting this protein from proteasomal degradation although we
cannot formally exclude subtle stabilizing effects or the possibil-
ity that p62 is only protected from proteasomal degradation un-
der speciﬁc conditions. The identiﬁcation of a protective UBA
domain that does not modify the half-lives of its natural host pro-
tein suggests that the ability of UBA domains to interfere with
proteasomal degradation may be an intrinsic feature of a subclass
of UBA domains. Direct comparison of the structural features of
protective and non-protective UBA domains may shed light on
the molecular mechanisms underlying their inhibition of prote-
asomal degradation.
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